A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Latest Information Update: 10 Feb 2025
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; BLI 1401 (Primary)
- Indications Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioLite Inc
Most Recent Events
- 07 Feb 2025 Planned End Date changed from 30 Jun 2026 to 30 Jun 2028.
- 07 Feb 2025 Planned primary completion date changed from 31 Dec 2025 to 31 Dec 2027.
- 07 Feb 2025 Planned initiation date changed from 1 Jan 2025 to 1 Jan 2026.